PL3618829T3 - Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem - Google Patents
Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworemInfo
- Publication number
- PL3618829T3 PL3618829T3 PL18794742.9T PL18794742T PL3618829T3 PL 3618829 T3 PL3618829 T3 PL 3618829T3 PL 18794742 T PL18794742 T PL 18794742T PL 3618829 T3 PL3618829 T3 PL 3618829T3
- Authority
- PL
- Poland
- Prior art keywords
- quinazoline
- cancer
- treatment
- related disorders
- pyridine derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- AMJZJYLMKHTSDG-UHFFFAOYSA-N pyridine;quinazoline Chemical class C1=CC=NC=C1.N1=CN=CC2=CC=CC=C21 AMJZJYLMKHTSDG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502391P | 2017-05-05 | 2017-05-05 | |
| US201862624273P | 2018-01-31 | 2018-01-31 | |
| PCT/US2018/030909 WO2018204661A1 (en) | 2017-05-05 | 2018-05-03 | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3618829T3 true PL3618829T3 (pl) | 2023-11-20 |
Family
ID=64016681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18794742.9T PL3618829T3 (pl) | 2017-05-05 | 2018-05-03 | Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11045472B2 (pl) |
| EP (1) | EP3618829B1 (pl) |
| JP (1) | JP7295034B2 (pl) |
| CN (1) | CN110612100B (pl) |
| ES (1) | ES2953349T3 (pl) |
| PL (1) | PL3618829T3 (pl) |
| TW (1) | TWI789393B (pl) |
| UY (1) | UY37725A (pl) |
| WO (1) | WO2018204661A1 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213377A1 (en) | 2017-05-17 | 2018-11-22 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
| CN109293586A (zh) * | 2018-11-22 | 2019-02-01 | 云南师范大学 | 一种在氨水中微波条件下卤代苯甲酸合成喹唑啉酮化合物的方法 |
| WO2020146563A1 (en) * | 2019-01-10 | 2020-07-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers such as spp to increase tumor immunity and improve the efficacy of cancer immunotherapy |
| AU2020239048B2 (en) | 2019-03-12 | 2025-10-16 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| JP7743309B2 (ja) | 2019-03-29 | 2025-09-24 | アーカス バイオサイエンシズ インコーポレイティド | 同定されたアデノシンフィンガープリントを利用したがんの処置 |
| TWI879779B (zh) * | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| IL295093A (en) * | 2020-01-30 | 2022-09-01 | Ona Therapeutics S L | Combination therapy for treatment of cancer and cancer metastasis |
| WO2021188769A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| AR122493A1 (es) | 2020-06-02 | 2022-09-14 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| CN117295741A (zh) | 2021-05-21 | 2023-12-26 | 艾库斯生物科学有限公司 | Axl化合物 |
| AU2022376961A1 (en) | 2021-10-29 | 2024-05-16 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| US20240124490A1 (en) | 2022-07-15 | 2024-04-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119462487A (zh) * | 2023-08-08 | 2025-02-18 | 重庆博腾制药科技股份有限公司 | 一种阿培利司中间体4-甲基吡啶类化合物的制备方法 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025096979A1 (en) | 2023-11-02 | 2025-05-08 | Arcus Biosciences, Inc. | Thiazole compounds as kit inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1397364E (pt) * | 2001-05-24 | 2007-10-22 | Lilly Co Eli | Novos derivados de pirrole como agentes farmacêuticos |
| TWI330183B (pl) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| WO2004106337A1 (en) | 2003-05-06 | 2004-12-09 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| WO2005058883A1 (en) * | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| TW200813056A (en) * | 2006-06-29 | 2008-03-16 | King Pharmaceuticals Res Dev Inc | Adenosine A2B receptor antagonists |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| US8871744B2 (en) * | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
-
2018
- 2018-05-03 US US16/610,812 patent/US11045472B2/en active Active
- 2018-05-03 JP JP2019560299A patent/JP7295034B2/ja active Active
- 2018-05-03 ES ES18794742T patent/ES2953349T3/es active Active
- 2018-05-03 EP EP18794742.9A patent/EP3618829B1/en active Active
- 2018-05-03 PL PL18794742.9T patent/PL3618829T3/pl unknown
- 2018-05-03 WO PCT/US2018/030909 patent/WO2018204661A1/en not_active Ceased
- 2018-05-03 CN CN201880029680.6A patent/CN110612100B/zh active Active
- 2018-05-04 UY UY0001037725A patent/UY37725A/es not_active Application Discontinuation
- 2018-05-04 TW TW107115270A patent/TWI789393B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201843150A (zh) | 2018-12-16 |
| EP3618829A4 (en) | 2021-01-06 |
| UY37725A (es) | 2018-10-31 |
| US20200069689A1 (en) | 2020-03-05 |
| EP3618829B1 (en) | 2023-06-07 |
| TWI789393B (zh) | 2023-01-11 |
| JP7295034B2 (ja) | 2023-06-20 |
| US11045472B2 (en) | 2021-06-29 |
| EP3618829A1 (en) | 2020-03-11 |
| CN110612100A (zh) | 2019-12-24 |
| ES2953349T3 (es) | 2023-11-10 |
| WO2018204661A1 (en) | 2018-11-08 |
| EP3618829C0 (en) | 2023-06-07 |
| JP2020518627A (ja) | 2020-06-25 |
| CN110612100B (zh) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| EP3618829C0 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-ASSOCIATED DISORDERS | |
| PL3634417T3 (pl) | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL267818A (en) | Methods for treating neurological disorders | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| IL258032B (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
| IL273835A (en) | Combined product for cancer treatment | |
| EP3371154A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| HK40101362A (zh) | 用於治疗癌症相关疾病的唑嘧啶 | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1260601A1 (en) | Heterocycle derivatives and their use for the treatment of cns disorders | |
| GB201602784D0 (en) | New treatment of CFTR-related disorders |